EXHIBIT 99.1

              Provectus Pharmaceuticals Announces Company Financing

Knoxville,  Tenn,  Provectus  Pharmaceuticals  (OTCBB: PVCT - News). - Provectus
Pharmaceuticals,  Inc. announces that in has completed  unsecured  financing for
the  company of  $500,000.  The total  financing  to the  company  would be $1.1
million after all warrants have been converted.  The financing was obtained from
a group of accredited investors.

"This  funding  allows  us  to  continue  the   advancement  of  our  innovative
proprietary drug therapies for breast,  liver and prostrate cancer and psoriasis
treatment  as well as the  Company's  line of over-the  counter  products"  said
Provectus CEO, Craig Dees, Ph.D.

Provectus  Pharmaceuticals  Inc. licenses and sells products in three sectors of
the health-care industry:  1)-prescription medications and treatment, 2) medical
devices,  and  3)  over-the-counter  (OTC)  pharmaceuticals.  Prescription  drug
products and devices  treat  diseases of the skin and many types of cancer.  OTC
products address complementary markets,  primarily those involving skin care and
comfort.

The  company's  offices and  laboratory  are located at 7327 Oak Ridge  Highway,
Suite A Knoxville,  TN 37931;  telephone:  865/769-4011.  For more  information,
contact the company at  info@provectuscorp.com  or visit the corporate Web site:
www.provectuscorp.com.

Forward-Looking  Statements
This  release  and  others  statements  issued  or made from time to time by the
company  or  its   representatives   contain   statements  that  may  constitute
forward-looking  statements.  Those statements include statements  regarding the
intent,  belief or  current  expectations  of the  company  and  members  of its
management  teams as well as the  assumptions on which the statements are based.
Prospective investors are cautioned that such forward-looking statements are not
guarantees of future performance and involve risks and  uncertainties,  and that
actual  results  may  differ   materially   from  those   contemplated  by  such
forward-looking statements.

- -------------------
Corporate Contact: Provectus Pharmaceuticals, Craig Dees, CEO (865) 769-4011

- -------------------
Source: Provectus Pharmaceuticals Inc.